Clinical Trial Update: A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) [Phase 2]

View source ↗

Summary

Phase 2 study of Calderasib (MK-1084) in adults with advanced malignant solid tumors is currently recruiting (NCT07209111), sponsored by Merck Sharp & Dohme LLC…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Neoplasms

Drugs mentioned

• Calderasib (MK-1084)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Neoplasm Malignant | Phase 2 | Status: RECRUITING